<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972204</url>
  </required_header>
  <id_info>
    <org_study_id>ART-2013-01</org_study_id>
    <nct_id>NCT01972204</nct_id>
  </id_info>
  <brief_title>Intensive Instruction on the Use of Aricept</brief_title>
  <official_title>A Study About the Impact of Intensive Instruction on the Use of Aricept and the Reasons for Discontinuation in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirai Iryo Research Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirai Iryo Research Center, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the influence of the instruction on the use of
      Aricept with educational brochure on the 48-week medication persistence and to assess the
      reasons for discontinuation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication persistence rate</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for discontinuation</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factor analysis for medication persistence</measure>
    <time_frame>48 weeks</time_frame>
    <description>Subgroup analysis with delineation of different factors associated with the degree of medication persistence with Aricept therapy: years of schooling, family living together, caregiver background, Category of Condition of Need for Long-Term Care, In-Home Long-Term Care Service, FAST, MMSE-J, the Level fo Independent Living of Demented Elderly, concomitant medication, BPSD, drug compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Week 2, 12, 24, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer's Type Dementia</condition>
  <arm_group>
    <arm_group_label>Intensive adherence instruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive adherence instruction</intervention_name>
    <description>Instruction with educational brochure</description>
    <arm_group_label>Intensive adherence instruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Instruction as per usual practice</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic evidence of probable Alzheimer's type Dementia consistent with DSM-IV.

          -  Written informed consent will be obtained from subject (if possible) or from the
             subject's legal guardian or other representative (according to Japanese regulations as
             appropriate) prior to beginning screening activities.

          -  Patients having caregivers who submit written consent for cooperative involvement in
             this study, can provide patients' information necessary for this study, assist
             treatment compliance, and escort patients on required visits to study institution.

          -  Outpatients in their own home.

        Exclusion Criteria:

          -  Patients treated with donepezil, galantamine, rivastigmine in 4 weeks immediately
             before enrollment.

          -  Known hypersensitivity to donepezil or piperidine derivatives.

          -  Involvement in any other investigational drug clinical trail during the preceding 12
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsumasa Kamei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Fujisawa Tokushukai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomoko Machida</last_name>
    <phone>+81-3-3263-4801</phone>
    <email>machida@mirai-iryo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Tsujidoukandai 1-5-1</city>
        <state>Fujisawa-City, Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tetsumasa Kamei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mirai Iryo Research Center, Inc.</investigator_affiliation>
    <investigator_full_name>Tetsumasa Kamei</investigator_full_name>
    <investigator_title>Hospital Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

